Important new trials to treat and prevent dementia are starting in Australia that give patients access to anti-amyloid antibodies that are proven to clear plaques and appear effective in slowing Alzheimer’s disease.
As a result, the ADNeT Screening program has resumed with strict adherence to COVID-19 safety measures. The ADNeT Screening program offers diagnostic certainty and the potential access to the new trials. It provides unique and fee access to leading-edge dementia diagnostics assessments, including amyloid and Tau PET scans, MRI brain scan, cognitive assessment – eligibility applies.
Contact ADNeT-Screening@unimelb.edu.au or (03) 9389 2938 for more information and to refer your patient.